Regeneron Pharmaceuticals (REGN) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] Regeneron Pharmaceuticals Inc (REGN) 3-Minute Overview ### 🎯 Layer 1: 30-Second Key Takeaways > **💡 One-Sentence Summary** > > Simply put, Regeneron is a high-margin biotech company that already prints a lot of cash from blockbuster drugs, while the market is also giving it credit for pipeline upside in areas like immunology and obesity. > **📍 Basic Profile** > > Market Cap **$79.9 billion** · Biotechnology · NASDAQ NMS - GLOBAL MARKET · Price **$755.51** > **⚡ 3 Things You Should Know** > > 1. 💰 Cash-rich biotech: REGN’s gross margin is an exceptional **86.56%** and net margin is **31.41%**, which tells you this is not a speculative “story stock” biotech—it’s already a very profitable drug company. > > 2. 📈 Growth is still there, but not explosive: 3-year revenue CAGR is only **5.62%** and 3-year EPS CAGR is **2.76%**, so the key debate is whether the pipeline can re-accelerate growth rather than just maintain a strong base business. > > 3. ⚖️ Valuation looks surprisingly reasonable: At about **17.6x** trailing earnings, the stock is not priced like a hype biotech, which basically means the market respects the business quality but is not fully pricing in a huge pipeline home run yet. > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Strong💪 | Net margin 31.41%, very strong for biotech | > | Growth Rate | Steady📈 | Revenue growth 5.62% (3Y CAGR) | > | Financial Health | Healthy💚 | Debt-to-equity 8.66%, very low leverage | > | Valuation | Fair | PE 17.61x | --- ### 📋 Layer 2: 2-Minute Deep Dive #### 📊 How Does This Company Make Money? **Business Model in One Sentence:** Regeneron develops and commercializes specialty biologic drugs, making money from product sales and partnered drug economics across large disease areas. **Revenue Breakdown:** | Business | Share | Trend | Comment | |----------|-------|-------|---------| | Commercialized medicines | [Data unavailable] | ↑ | Core profit engine; approved drugs fund R&D and reduce binary biotech risk | | Collaboration / partnered programs | [Data unavailable] | → | Important for upside, but can make results lumpier quarter to quarter | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |--------|-------|---------|----------------| | Gross Margin | 86.56% | Top tier | Very high pricing power and favorable economics from successful biologics | | Net Margin | 31.41% | Top tier | Converts a large share of revenue into bottom-line profit, rare in biotech | | ROE | 14.83% | Good 15% / Average | Solid returns, though not ultra-high for a company with this level of profitability | --- #### 📈 How's the Growth? **Growth Assessment:** Steady Growth | Metric | Latest | vs Last Year | Trend | |--------|--------|--------------|-------| | Revenue Growth | 5.62% (3Y CAGR) | [Data unavailable] | Stable to modest | | Profit Growth | 2.76% (3Y EPS CAGR) | [Data unavailable] | Slowing vs revenue | **Growth Quality:** > What’s interesting is that REGN’s growth looks real, not financially engineered—the company has strong margins, strong cash generation, and no obvious balance-sheet stress. But it’s also not in a “hypergrowth” phase anymore, so future upside likely depends on new indications, pipeline execution, and whether newer programs can offset maturity in existing franchises. --- #### 💰 Financial Health Check **One Sentence:** This looks like someone with a very high income, lots of cash in the bank, and barely any debt. | Metric | Value | Safe Zone | Assessment | |--------|-------|-----------|------------| | Debt Ratio | 8.66% | <60% safe | ✅Safe | | Current Ratio | 4.13 | >1.5 healthy | ✅Safe | | Cash Flow | $38.82/share | >0 | ✅Positive | --- #### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: $476.49 - 52-Week High: $821.11 - Current: $755.51, **very close to the high** | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current** | | | ●(80.9% position) | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |------------|---------|-----------|------------| | vs Own History | PE 17.61x | [Data unavailable] | [Data unavailable] | | vs Peers | PE 17.61x | [Industry avg unavailable] | [Data unavailable] | **What the Current Valuation is Betting On:** > Basically, the market seems to be betting on two things at once: first, that Regeneron can defend its existing profit machine; second, that pipeline and label-expansion wins—especially around Dupixent-related momentum and obesity optionality—can keep earnings from flattening out. --- #### 📰 Any Recent News? | Date | Event | Impact | |------|-------|--------| | 2026-03-24 | Japan approved Dupixent for bullous pemphigoid | Positive — expands addressable market and reinforces lifecycle value of an existing blockbuster | | 2026-03-11 | Positive obesity Phase 3 trial results drew attention | Positive — gives the stock another growth narrative beyond mature core products | | 2026-04-01 | Zacks rating upgrade to Buy | Neutral to Positive — helps sentiment, though rating changes matter less than actual drug data | | 2026-04-10 | Jim Cramer said the stock may be “breaking out” | Neutral — supportive for momentum, but not a fundamental thesis by itself | --- ### 📊 Layer 3: Want More? 3-Minute Complete Analysis #### I. Detailed Financial Data **Profitability Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Gross Margin | 86.56% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Net Margin | 31.41% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | ROE | 14.83% | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Revenue Growth | 5.62% (3Y CAGR) | [Data unavailable] | [Data unavailable] | → | | Profit Growth | 2.76% (3Y EPS CAGR proxy) | [Data unavailable] | [Data unavailable] | → | | EPS Growth | 2.76% (3Y CAGR) | [Data unavailable] | [Data unavailable] | → | --- #### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | 2025-12-31 | $10.83 | $11.44 | +5.65% Beat 😀 | | 2025-09-30 | $9.78 | $11.83 | +20.96% Beat 😀 | | 2025-06-30 | $8.61 | $12.89 | +49.77% Beat 😀 | | 2025-03-31 | $9.00 | $8.22 | -8.66% Miss 😟 | **Earnings Trend Interpretation:** Worth noting: after one miss in early 2025, REGN delivered three straight beats, and not just small ones. In other words, earnings expectations may have been too conservative, which usually supports confidence in execution and can help the stock hold a premium multiple. --- #### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |--------|-------|------------| | Strong Buy/Buy | 30 firms | 78.95% | | Hold | 8 firms | 21.05% | | Sell | 0 firms | 0.00% | **Target Price:** [Data unavailable] ~ [Data unavailable] (Median [Data unavailable]) **vs Current Price:** [Data unavailable] **Insider Activity:** Net selling in past 3 months based on available filings > The recent insider activity shown here is mostly very small sales by one insider, Arthur F. Ryan. That’s not a screaming red flag by itself, but it also doesn’t give you the bullish signal that meaningful insider buying would. --- #### IV. Key Risk Alerts **3 Risks to Watch:** 1. **Pipeline execution risk:** Biotech valuations can change fast if a major late-stage program disappoints → If this happens, it could lead to slower long-term growth and multiple compression. 2. **Growth concentration risk:** A lot of investor optimism seems tied to expanding key franchises and adding new pipeline wins → If those catalysts fade, the stock could remain profitable but trade more like a slower-growth pharma name. 3. **Near-high share price risk:** The stock is already at about **81%** of its 52-week range → If upcoming results are merely “good” instead of “great,” upside could be limited in the short run. --- ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** Regeneron is a mature, highly profitable biotech with real commercial scale, not an early-stage binary bet. > > **Key strength:** Its combination of huge margins, low debt, and repeated earnings beats gives it a very strong operating foundation. > > **Key risk:** The main question is not survival but re-acceleration—whether the pipeline can push growth back above the current modest pace. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis > > • Want to check for hidden landmines? → Try【Muddy Mode】for risk screening > > • Is this a growth stock? Want to calculate if it's worth the bet? → Try【Musk Mode】for analysis